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Pulmonary arterial hypertension (PAH) remains an 
impor  tant cause of mortality and morbidity in systemic 
sclerosis (SSc). Classiﬁ  cation of PAH as Group 1 within 
the Pulmonary Hypertension (PH) WHO clinical classi-
ﬁ  cation system has permitted inclusion of patients with 
SSc in numerous interventional trials and has resulted in 
the licensing of many agents, including endothelin 
receptor antagonists [1], type V cGMP phosphodiesterase 
inhibitors and prostacyclins, including parenteral and 
inhaled delivery systems. While this has been a fortunate 
circumstance for our patients, numerous critically 
impor  tant questions remain unaddressed. In general, 
although the recently updated classiﬁ  cation of PH retains 
SSc cases within Group 1 [2], evidence suggests that 
patients with PAH related to SSc (PAH-SSc) show 
blunted responses to therapy when compared with those 
with idiopathic PAH, including key measures of outcome 
such as the six-minute walk test, time to clinical 
worsening and survival [3]. Th  e very presence of SSc 
provides an enriched population at high risk of PAH and 
should oﬀ   er the opportunity for early diagnosis, yet 
registry and centre-based data reveal no improvement in 
referral intervals. Part of this may reﬂ  ect an increased 
understanding of the lack of sensitivity and speciﬁ  city of 
echocardiography, particularly at the lower end of 
pulmonary pressures but also because of confounding 
issues posed by concomitant interstitial lung disease. 
Finally, patients with SSc tend to be under-represented in 
modern trials, which are typically rather short in duration 
(12 to 18  weeks), result  ing in inadequacy of data to 
support deﬁ  nitive recom  mendations [4].
With this background, there has recently been a 
systematic eﬀ   ort to improve the assessment of PAH 
occurring in association with SSc. Th  e main drivers for 
this have included a desire for better validated endpoints 
that could be used as a core set applied to clinical trials, 
the wish for a clinically meaningful endpoint that would 
reﬂ  ect practice, and the need for less invasive longitudinal 
assessment tools that might replace right heart catheteri-
sation (RHC) as the perceived gold standard test for PAH. 
At present, RHC is essential for diagnosis but there are 
questions about the feasibility of this as a tool to follow 
patients clinically over time. Th  ere is clear need for a 
non-invasive endpoint as well as for validation and 
critical analysis of the eﬀ  ectiveness of screening modali-
ties. Th   ere are particular challenges in addressing this for 
PAH-SSc, a condition that requires multidisciplinary care 
and that may present and be followed up by a number of 
diﬀ  erent subspecialists. Each will be an expert in their 
own ﬁ  eld and be familiar with managing and interpreting 
certain investigations but there will be diﬀ  erences  of 
opinion between the diﬀ  erent experts as to what the best 
tests are and how they should be interpreted and used in 
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© 2011 BioMed Central Ltdpractice. In addition, the tools that may be validated in 
other forms of PAH are unlikely to have been formally 
assessed in PAH-SSc, which has its own unique 
characteristics that may aﬀ  ect standard PAH outcome 
measures; an example would include the asso  ciated 
musculoskeletal manifestations. Moreover, there may be 
diﬀ  erences for other forms of connective tissue disease-
associated PAH. Th   ere are biases introduced based upon 
diﬀ   erent clinical experiences and also related to the 
familiarity with clinical trials.
An approach that has been used successfully in 
rheumatology and has a clearly deﬁ   ned framework is 
covered by the Outcome Measures in Rheuma  tology 
(OMERACT) methodology. Th  is uses a standardised 
frame  work to assess potential disease measures for clinical 
trials to consider utility under the subcategories of the 
OMERACT ﬁ   lter [5]. Th  e Expert Panel on Outcomes 
measures in PAH related to Systemic Sclerosis (EPOSS)-
OMERACT group was established to begin to apply this 
approach to evaluating PAH-SSc. Th   is group has 
integrated expertise in cardiology, pulmonary medicine, 
rheumatology and biostatistics as well as clinical trial 
design and outcome development and validation. It has 
applied the OMERACT ﬁ   lter to individual tools that 
could represent endpoints in trials and has critically 
reviewed the published literature to explore the extent to 
which outcomes have been validated. In addition, it has 
sought to develop consensus about individual outcomes. 
In particular, the EPOSS group has identiﬁ  ed through a 
Delphi process a series of recommended domains and 
their assessment tools [6]. Th  e data that could validate 
these tools have been considered systematically and this 
has led to a series of important observations. One of the 
goals was to identify a measure or series of measures that 
could replace RHC as the gold standard of assessment. 
Th   ese are signiﬁ  cant achievements and have resulted in a 
series of relevant publications. So far, six substantive 
papers [6-11] have been published as a direct result of the 
EPOSS initiative, and more are expected.
Work is now underway and there will be attempts to 
validate the individual components and to review the 
available data that provide some validation. Th  is is a 
daunting task as for many tools there are not suﬃ   cient 
results from research studies to undertake this. First 
attempts to evaluate the routine clinical tool of Doppler-
echocardiography are testament to the challenge that lies 
ahead [7]. An important output of this exercise has been 
the deﬁ  nition of research agenda to prioritise eﬀ  ort in 
addressing the data that are available and determine the 
extent to which the available information from national 
(such as the French Intinair project [12], UK single centre 
registries and compERA-XL [13]) or from clinical trial 
datasets might be interrogated. One limitation of most 
clinical trials is that they usually include a minority, 
typically around 20%, of cases with connective tissue 
disease-associated PAH, and fewer with PAH-SSc. Th  e 
EPOSS group provides a template for the type of 
international multidisciplinary approach that could 
tackle these important challenges.
In the meantime the clinical arena has moved on and a 
large number of major clinical trials in PAH include cases 
of PAH-SSc. Th   ere has been the strong suggestion that a 
composite endpoint that reﬂ  ects clinical practice be used. 
Th   is has become deﬁ  ned as the time to clinical worsening 
(TTCW). A formal measure of TTCW has emerged as an 
attractive composite endpoint that measures progression 
in PAH. It was originally included as a secondary end-
point in several major clinical trials that led to licensing 
of PAH therapies based upon a primary endpoint of 
change in exercise capacity (the six-minute walk test). At 
face value it makes obvious sense, especially as a clinically 
meaningful endpoint that may be used in licensing and in 
post-licensing evaluation of therapies. However, the devil 
is in the detail. Diﬀ   erent studies have used diﬀ  erent 
components in the TTCW deﬁ  nition and there are major 
potential local diﬀ  erences in practice that may make a 
measure unworkable or unreliable in diﬀ  erent centres. 
Th  us, some centres have an outpatient ambulatory 
emphasis whereas others may often hospitalise cases of 
PAH. In addition, availability of therapies and expertise 
in procedures such as surgical intervention or 
transplantation may be relevant. More  over, as discussed 
above, it is likely that diﬀ   erent standards may be 
applicable for PAH-SSc versus idiopathic PAH due to co-
morbidity and potential diﬀ   erences between outcome 
and progression of PAH and suitability for treatments. In 
the short term, TTCW is very likely to be adopted as a 
useful measure and one that is especially relevant in early 
stage disease where stabilisation can be a very appropriate 
management goal. However, this should serve as an 
impetus to further research to validate and understand 
individual compo  nents of TTCW and develop new and 
potentially better composite tools. In particular, there are 
self-evident reasons why some of the components of 
TTCW are likely to be unreliable or incomparable in 
PAH-SSc. Musculo  skeletal involvement and co-
morbidity, such as lung ﬁ  brosis or cardiac complications, 
are clearly likely to aﬀ  ect exercise capacity. One study 
suggests that musculo  skeletal deconditioning is the 
major determinant of six-minute walk test distance [14], 
and no relationship with parameters of lung function has 
been shown [15]. Th  ere are multiple causes of disease-
related mortality in SSc - for example, renal crisis, lung 
ﬁ   brosis and gut disease - and so mortality cannot be 
taken as a surrogate for PAH outcome. Finally, co-
morbidity and age make PAH-SSc cases much less likely 
than idiopathic PAH to be referred for transplantation 
and even less likely to be transplanted. Th  e impact of 
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out in a composite score but this cannot be assumed. 
Th   is should be considered especially in subtypes of PAH 
and so the research work now emerging from the EPOSS 
initiative is likely to be very relevant. In the meantime, 
the recent report from the Fourth World Congress in PH 
in Dana Point, USA, represents current best expert 
consensus on how to standardise and use TTCW as an 
outcome measure in PAH clinical trials [16]. It seems 
likely that TTCW will be a benchmark in future studies. 
It has already replaced exercise capacity assessed by the 
six-minute walk test distance, generally now there is a 
move towards a robust hemodynamic endpoint or the 
composite clinical measure.
So where does that leave the EPOSS initiative? Th  e 
work could be regarded as done and the TTCW be 
adopted as a gold standard. RHC would remain for 
diagnosis but would only be performed later as directed 
clinically. But this would not be a correct approach for 
PAH-SSc. Table 1 highlights some speciﬁ  c aspects that 
would be relevant to the domains and measures that have 
been identiﬁ   ed through the EPOSS initiative and that 
may be incorporated into composite endpoints, including 
TTCW. Th   ere is a strong need for systematic validation 
and much to be learnt from the deﬁ  ned research agendas 
along the way. Th   e two concepts must co-exist but cannot 
do so without interplay so that both may inform the 
other. It can be argued that rigorous concerns about 
validity of endpoints could have severely impeded pro-
gress and treatment opportunities but the challenge must 
now be faced so that there is a real consensus that can be 
applied and eventuality the clinical needs of patients and 
the methodological needs of trialists and the exacting 
standards of the regulatory authorities that license new 
agents can all be met. For the time being TTCW is 
probably the most usable endpoint for clinical studies but 
the component terms need better standardisation and 
must be clearly deﬁ  ned. In the future, through initiatives 
such as EPOSS, these components can be validated in 
PAH-SSc and it is imperative that the challenge of this 
task is not used as justiﬁ  cation for not addressing these 
important questions.
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